Sophos IRB Launches as the First Independent Central IRB Company Dedicated to Oncology

Company-wide oncology specialization brings more than 105 years of combined oncology experience to clinical research oversight

RALEIGH, N.C., Aug. 31, 2026 /PRNewswire/ -- Sophos IRB, an independent central Institutional Review Board, today announced its launch as the first independent central IRB company dedicated to oncology, introducing a specialized model for the ethical and regulatory review of oncology clinical research.

Sophos has taken a distinct approach to central IRB review by making oncology the primary focus of the organization. The company has assembled an IRB roster with more than 105 years of combined oncology experience and built its review model and operations around the needs of oncology sponsors, CROs, institutions and research sites.

"Oncology has evolved into an extraordinarily specialized area of clinical research, but the central IRB model has remained largely generalist," said Brandon Evans, Chief Executive Officer of Sophos IRB. "We believe there is value in bringing the same degree of specialization to ethical and regulatory review that sponsors increasingly expect across the rest of oncology drug development. Sophos was founded around that premise."

For Sophos, oncology is not a service line or one therapeutic area among many; it is the company's defining focus. The company's strategy is centered on long-term depth in oncology rather than operating as a broad therapeutic-area platform.

"We've built Sophos to be the IRB of choice for oncology," Evans said. "That means combining deep therapeutic experience with regulatory rigor and a level of responsiveness that sponsors and CROs should expect from a specialized partner."

About Sophos IRB

Sophos IRB is an independent central Institutional Review Board dedicated to the ethical and regulatory review of oncology clinical research. With more than 105 years of combined oncology experience across its IRB roster, Sophos provides central IRB review and ongoing oversight for sponsors, CROs, institutions and research sites.

For more information, visit www.sophosirb.com.

Media Contact:
Alexa Spain
[email protected]

SOURCE Sophos IRB, Inc.